Clinical Relevance of the Linkage between Environmental Toxicant Exposures and Alzheimers Disease and Related Dementias (R01 Clinical Trial Not Allowed) | PAR 22 048

Opportunity Information: Apply for PAR 22 048

The NIH funding opportunity PAR 22-048 supports R01 research projects that dig into the clinical relevance and biological plausibility of links between environmental toxicant exposures and Alzheimers disease and related dementias (AD/ADRD). The central problem it is trying to solve is that, even though many human studies report associations between toxicant exposure and dementia outcomes, the field still lacks enough mechanistic evidence to clarify whether these exposures actually contribute to disease initiation, accelerate progression, or modify disease pathways in a meaningful way. This mechanistic gap makes it hard to move from correlation to causation, and it also slows progress on prevention strategies, risk reduction, and policy actions that could reduce exposure-related risk.

A major emphasis of the announcement is on understanding how neurotoxicants act on the nervous system in ways that intersect with known AD/ADRD biology. The NIH is specifically encouraging neuroscience-focused projects that can test and explain mechanisms, rather than simply documenting additional epidemiologic associations. The work is framed as particularly important for addressing potentially modifiable drivers of racial and socioeconomic inequities, since toxicant exposures often differ by neighborhood, occupation, housing conditions, and other structural factors that track with race, ethnicity, and income. In other words, the program is positioned not only as basic and translational neuroscience, but also as a pathway toward understanding preventable contributors to unequal dementia burden.

The scientific scope is broad and flexible, and it explicitly welcomes multiple experimental approaches. Proposed studies may use in silico modeling to predict or simulate how specific chemicals interact with biological targets relevant to AD/ADRD, including pathway-level and systems-level modeling. They may also develop or refine in vitro assays that connect chemical exposure to Alzheimer-relevant cellular phenotypes, such as effects on amyloid and tau pathways, synaptic function, neuroinflammation, oxidative stress, mitochondrial dysfunction, vascular contributions to cognitive impairment, or other disease-relevant mechanisms. In vivo work is also a key part of the scope, especially studies that test whether neurotoxicants can modify established AD/ADRD targets and pathways, and the reverse question as well: whether canonical targets for particular neurotoxins overlap with, or help drive, AD/ADRD etiology.

Another priority area is the development and validation of animal models that better reflect real-world exposure scenarios in humans. This includes neuropathological, neurophysiological, and neurobehavioral models that can reproduce relevant exposure routes, timing, intensity, and mixtures where appropriate. The announcement highlights the value of lifespan comparisons when feasible, recognizing that exposure during development, early adulthood, midlife, or late life could have different consequences for brain aging and dementia risk. Overall, the program is trying to strengthen the chain of evidence from exposure to mechanism to clinically meaningful disease outcomes, using experimental designs that can establish plausibility and, where possible, causal inference.

From an administrative standpoint, this is an NIH discretionary grant using the R01 mechanism, and it is labeled "Clinical Trial Not Allowed," meaning applicants should not propose prospective clinical intervention trials that meet NIH’s definition of a clinical trial. It falls under CFDA numbers 93.853 and 93.866. The opportunity lists an award ceiling of $500,000 (as provided in the source data) and was originally posted with a closing date of 2022-03-11, with a creation date of 2021-10-13.

Eligibility is broad and includes many types of U.S. organizations and governments: state, county, city/township, special district governments, independent school districts, public and state-controlled institutions of higher education, private institutions of higher education, federally recognized tribal governments, tribal organizations that are not federally recognized, public housing authorities/Indian housing authorities, nonprofits with or without 501(c)(3) status (outside of higher education), for-profit organizations other than small businesses, and small businesses. The announcement also calls out additional eligible applicant categories that reflect a strong interest in diverse institutional participation and community-relevant research capacity, including Alaska Native and Native Hawaiian Serving Institutions, AANAPISIs, Hispanic-serving institutions, HBCUs, Tribally Controlled Colleges and Universities, faith-based or community-based organizations, eligible federal agencies, U.S. territories or possessions, regional organizations, and even non-U.S. entities (foreign organizations). Taken together, the eligibility language signals an intent to attract a wide range of mechanistic neuroscience teams, including institutions serving populations that may be disproportionately affected by environmental exposures and dementia risk.

• The National Institutes of Health in the health sector is offering a public funding opportunity titled "Clinical Relevance of the Linkage between Environmental Toxicant Exposures and Alzheimers Disease and Related Dementias (R01 Clinical Trial Not Allowed)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.853, 93.866.
• This funding opportunity was created on 2021-10-13.
• Applicants must submit their applications by 2022-03-11. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Each selected applicant is eligible to receive up to $500,000.00 in funding.
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for PAR 22 048

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: